Home › NDC Lookup › Ingredients › Lidocaine › 84938-0003-01
🧴image loading
(from DailyMed)

NDC 84938-0003-01: Black Cobra Tattoo NumbingSpray 4% Lidocaine .04 g/mL Liquid, 30 mL Bottle

by Foshan Sugar Max Cosmetics CO.,Ltd

This is a package of 30 mL of Black Cobra Tattoo NumbingSpray 4% Lidocaine .04 g/mL Liquid from Foshan Sugar Max Cosmetics CO.,Ltd, first listed with the FDA May 2025 and currently FDA-listed. It is this product's only package size.

🏷️ FDA NDC (as labeled) 84938-003-01 billing pads the product segment with a zero
OTC FDA-listed Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Nov 19, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 84938-003-01 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
84938 labeler · 003 product · 01 package
Package marketed since
May 26, 2025
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 8493800301 3
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Lidocaine (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Aug 31, 2026 — Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH). (SUN PHARMA /TARO) · FDA recall D-0848-2026
Class III · Apr 20, 2023 — Labeling: Typographical error on the upper left-hand side of the box and individual patch label that has the incorrect dosage form stating, each tablet contains instead of each adhesive patch contains. (Bryant Ranch Prepack, Inc.) · FDA recall D-0556-2023
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 84938-003-01
Product NDC 84938-003
11-digit billing NDC 84938000301
RxCUI 1869797
UNII 98PI200987
Application # M017
SPL Set ID 3605fcbf-63c8-87b5-e063-6294a90a9c3e
Established class (EPC) Amide Local Anesthetic; Antiarrhythmic
Physiologic effect Local Anesthesia
Chemical class Amides
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status FDA-listed
FDA listing status Listed (active directory)
Marketing start 2025-05-26
Route TOPICAL
Dosage form LIQUID
Substance LIDOCAINE
Quick answers
  • RxCUI (RxNorm): 1869797
Why two NDCs? The FDA registers this code as 84938-003-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 84938-0003-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Antiarrhythmic class.

Pharmacologic class Antiarrhythmic, Amide Local Anesthetic
Drug family (ATC) Antiarrhythmics, class Ib, Local anesthetics, Anesthetics for topical use
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📗 Our plain-language guide HelloPharmacist
  • Lidocaine numbs the area where it's applied or injected. Depending on the product, it's used for nerve pain after shingles, minor pain, itching, burns and insect bites, mouth and t...
  • Numbness generally starts within about 20 seconds to 1 minute and lasts roughly 5 to 30 minutes. Some products, such as Hilook Blue Gel Anesthetic, list a 15 to 30 minute wait. The...
  • Mild reactions include dizziness, drowsiness, nervousness and a brief burning at a patch site. Call for help if you have ringing in the ears, a metallic taste, confusion, twitching...
  • Better not to. The toxic effects of local anesthetics add together, and patch labels say not to use them with other topical pain relievers or more than one patch at a time. Ask me...
📖 Read our full Lidocaine guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
84938-0003-01 You're viewing this Main listing 30 mL in 1 BOTTLE 2025-05-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Walgreens pain relieving 4 g/100g 00363-3038-04 Walgreens 113 g — — FDA listed —
Aspercreme with Lidocaine Dry 4 g/100mL 41167-0583-05 Chattem, 113 ml — — FDA listed —
Burn Relief 40 mg/g 51316-0501-04 CVS 113 g — — FDA listed —
Lansinoh Pain Relieving 4 g/100mL 53997-0001-02 Lansinoh 1 bottle — — FDA listed —
Foot and Leg Pain Relief 40 mg/g 56104-0007-01 Premier 113 g — — FDA listed —
Bactine Max Dry 4 g/100g 65197-0815-04 WellSpring 175 ml — — FDA listed —
Fast Freeze Lidocaine 40 mg/mL 66902-0225-04 Natural 118 ml — — FDA listed —
Lidocaine Pain Relief 4 g/100g 69396-0178-04 Trifecta 113 g — — FDA listed —
Lidocaine Dry 4 g/100mL 69842-0543-04 CVS 113 ml — — FDA listed —
HealthWise Lidocaine Pain Relief 4 g/100mL 71101-0068-01 Veridian 113 ml — — FDA listed —
HealthWise Maximum Pain Relief 4 g/100mL 71101-0078-01 Veridian 113 ml — — FDA listed —
DCH Pain Relief 4 g/100g 72839-0226-04 Derma 113 g — — FDA listed —
Black Cobra Tattoo NumbingSpray 4% Lidocaine .04 g/mLthis 84938-0003-01 Foshan 30 ml — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2025
Listed with the FDA since
May 2025
📍
2026
Currently FDA-listed
1 year listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Lidocaine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
  • UNII 3XUS85K0RA
    Butylene glycol is a clear liquid derived from petroleum or plants that acts as a humectant, solvent, and preservative booster in medicines. It helps keep formulations stable, dissolve active ingredients, and maintain moisture in topical products.
  • UNII 147D247K3P
    Ethylhexylglycerin is a synthetic preservative used to prevent bacteria and mold from growing in medicines and personal care products. It helps keep the product safe and stable throughout its shelf life.
  • UNII 6K23F1TT52
    Kojic acid is a naturally derived compound used as a preservative and antioxidant in medicines. It helps prevent spoilage and maintain product stability during storage.
  • UNII HIE492ZZ3T
    Phenoxyethanol is a synthetic preservative and antimicrobial agent used to prevent bacterial and fungal growth in medicines and cosmetic products, extending shelf life and maintaining product safety.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII YSE9PPT4TH
    Hyaluronate sodium is a natural carbohydrate that holds moisture. It's used in medicines as a lubricant, thickener, and moisture-retaining agent to improve texture and delivery of the active ingredient.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 1Q73Q2JULR
    Sodium citrate is a salt derived from citric acid. It works as a buffer to maintain the medicine's pH level and may also help improve taste or act as a preservative in the formulation.

9 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesAqua Propylene Glycol Sodium Hyaluronate Kojic Acid Sodium Hydroxide Trisodium Citrate 1,3-Butanediol Phenoxyethanol Ethylhexylglycerin

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerFoshan Sugar Max Cosmetics CO.,Ltd
FDA applicationM017 (OTC MONOGRAPH DRUG)
Labeler code84938
First marketedMay 2025
Product typeHuman Otc Drug
Portfolio19 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 19 words ▾

Temporarily relieves pain and itching due to: Tattoo procedures, Minor scrapes, Minor cuts, Minor skin irritations, Tattoo Laser Remova

⏱️ Dosage and Administration 45 words ▾

Adults and children 12 years and older: Apply a generouslayerto the affected area 15-30 minutes before the procedure.Allow the anesthetic to take effect, For prolonged comfort,reapply as necessary, but do not exceed 3 applications in 24hours. Children under 12 years: Consult a doctor before use.

⚠️ Warnings 4 words ▾

For external use only

🧪 Active Ingredient 2 words ▾

Lidocaine 4%

🧪 Inactive Ingredients 14 words ▾

Aqua Propylene Glycol Sodium Hyaluronate Kojic Acid Sodium Hydroxide Trisodium Citrate 1,3-Butanediol Phenoxyethanol Ethylhexylglycerin

🎯 Purpose 2 words ▾

External Analgesic

📄 When Using This Product 35 words ▾

Keep out of reach of children. Not foruse on children under 12 years old, consult a doctor beforeuse. Avoid contact with eyes, mouth, or open wounds. Do not apply over large areas of the body.

📄 Stop Use and Ask a Doctor If 23 words ▾

Stop use and seek medicaattention if irritation, rash, or an allergic reaction occurs, or ifsymptoms worsen or persist for more than seven days.

📄 Keep Out of Reach of Children 18 words ▾

lf swallowed, get medical help or contact Poison Control at 1-800-222-1222.Store at room temperature and do not freeze

📄 Package Label / Principal Display Panel 1 words ▾

label2

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Lidocaine (matched by generic name) — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Lidocaine. CMS lists 8 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$53.12M
Claims incl. refills
593.7K
Beneficiaries
367.9K
Spend / beneficiary
$144.39
Spend / claim
$89.46
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Black Cobra Tattoo NumbingSpray 4% Lidocaine (this brand).

Top reported reactions

Pain3,213
Fatigue3,108
Nausea3,094
Headache2,854
Dyspnoea2,216
Pneumonia2,054
Diarrhoea2,011

Age at onset

Neonate149
Infant67
Child372
Adolescent264
Adult5,049
Elderly3,248

Reporter sex

49,632 reports
Male · 37%
Female · 63%
Unknown · 0%

Serious outcomes

Hospitalization17,856
Death5,053
Life-threatening4,303
Disabling1,215
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 5,396 3,212
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Foshan Sugar Max Cosmetics CO.,Ltd. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Foshan Sugar Max Cosmetics CO.,Ltd is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.